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Protein turnoverPeople with diabetes experience chronic hyperglycemia and are at a high risk of developing atherosclerosis
and microvascular disease. Reactions of glucose, or aldehydes derived from glucose (e.g. methylglyoxal,
glyoxal, or glycolaldehyde), with proteins result in glycation that ultimately yield advanced glycation end
products (AGE). AGE are present at elevated levels in plasma and atherosclerotic lesions from people with
diabetes, and previous in vitro studies have postulated that the presence of these materials is deleterious to
cell function. This accumulation of AGE and glycated proteins within cells may arise from either increased
formation and/or ineffective removal by cellular proteolytic systems, such as the proteasomes, the major
multi-enzyme complex that removes proteins within cells. In this study it is shown that whilst high glucose
concentrations fail to modify proteasome enzyme activities in J774A.1 macrophage-like cell extracts, reactive
aldehydes enhanced proteasomal enzyme activities. In contrast BSA, pre-treated with high glucose for
8 weeks, inhibited both the chymotrypsin-like and caspase-like activities. BSA glycated using methylglyoxal
or glycolaldehyde, also inhibited proteasomal activity though to differing extents. This suppression of
proteasome activity by glycated proteins may result in further intracellular accumulation of glycated
proteins with subsequent deleterious effects on cellular function.A, bovine serum albumin; DTT,
ethylglyoxal; PBS, phosphate-
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ll rights reserved.© 2010 Elsevier B.V. All rights reserved.The continuous synthesis and degradation of proteins plays an
essential role in the maintenance of cellular homeostasis and
regulation of multiple cellular functions [1,2]. This continuous protein
turnover minimises protein exposure to oxidants or other damaging
agents, and therefore reduces the potential accumulation of materials
with a modiﬁed structure or function [1]. However, despite this
continuous turnover of proteins inmost cells and tissues, evidence has
been presented for an accumulation of modiﬁed proteins in a wide
range of age-related diseases including Alzheimer's disease, Parkin-
son's disease, cataractogenesis, atherosclerosis and diabetes [3,4]. This
accumulation implies either an increased rate of formation of
damaged proteins or a decreased rate of removal, or both.
People with diabetes have elevated levels of modiﬁed proteins
arising from glycation and glycoxidation reactions [5]. Glycated
proteins arise from the nonenzymatic reaction of glucose, and reactive
aldehydes derived from glucose, with proteins, lipids and nucleic
acids. These reactions ultimately yield advanced glycation endproducts (AGE) [6,7]. In a normal healthy population the level of
glycated products on plasma proteins (e.g. albumin) is b3%, whilst in
people with diabetes this proportion can be increased very dramat-
ically [8,9]. Elevated levels of a number of low molecular mass
aldehydes, including glyoxal (GO), methylglyoxal (MGO), 3-deox-
yglucosone and glycolaldehyde (GA) have also been detected in
people with diabetes [6]. GA can be generated from glucose and amino
acid oxidation [10], GO from glucose oxidation [11] andMGO from the
degradation of glucose, glycerone phosphate, glyceraldehyde-3-
phosphate, acetone, aminoacetone and amino acid oxidation [12–
14]. Glycation reactions occur more rapidly with reactive aldehydes,
such as GA, GO andMGO, than with glucose [6,15]. The elevated levels
of these reactive aldehydes can be due to an increase in the rate of
generation of these aldehydes [13] and/or deﬁciencies in their
removal systems [13,16,17]. Previous studies have reported an
upregulation of systems that detoxify these reactive aldehydes,
including glyoxalases (glyoxalase I and II) [13,16,17] and aldose
reductase [16]. However, these systems do not appear able to
compensate adequately for an increased formation of reactive
aldehydes in people with diabetes, and particularly those with
complications [13,16,17].
When primary cellular defences, such as protein disulﬁde
isomerases (which reduce disulﬁde bonds), methioine sulfoxide
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molecular chaperones (which refold partially denatured proteins) are
unable to repair damage to proteins, the altered proteins are targeted
for degradation by cellular protein removal systems [1]. The two
major systems in eukaryotic cells responsible for this action are the
endo-lysosomal system and proteasomes [3]. The latter, which are the
major proteolytic pathway for intracellular proteins, are members of a
class of proteases known as the N-terminal nucleophile hydrolases
[18,19]. The 26S proteasomal complex appears to account for the
majority of the ATP- and ubiquitin-stimulated proteolytic activity, and
consists of a 20S proteolytic core and one or two 19S regulatory units
[18,20,21]. There are three different types of active sites; two
chymotrypsin-like (β5 subunit), two trypsin-like (β2 subunit) and
two caspase-like (or PGPH) (β1 subunit). The activities of each of
these three sites need to be evaluated in order to obtain a complete
picture of the state of the proteasomal system inside cells, or the
potency of inhibitors [21]. Previous studies have reported an age-
related decline in the peptidase activities of the 20S and 26S
proteasome in humans, with this decrease postulated to give rise to
an accumulation of damaged proteins [22].
Reactive aldehydes (MGO, GO and GA) and pre-glycated proteins
have been reported to alter cellular function via suppression of the
activity of key cellular enzymes including glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, a key glycolytic enzyme), glutathione reduc-
tase (GR, an important antioxidant enzyme), and lactate dehydrogenase
(LDH) [23]. These aldehydes have also been demonstrated to inhibit
cysteine proteases (cathepsins B, L and S) of the lysosomal cathepsin
family inmacrophage cell lysates in a concentration-dependentmanner
[7]. Under the same conditions glucose, or proteins pre-glycated with
glucose had no effect [7,23]. This inhibition has been suggested to arise
from aldehyde-induced modiﬁcation of the thiol groups of these
enzymes [7,23]. It has also been suggested that elevated levels of free
lowmolecularmass aldehydes (GA, GO andMGO) play an essential role
in diabetes-associated atherosclerosis via the formationof glycated low-
density lipoprotein particles which may contribute to lipid-loading of
macrophage cells in the artery wall [24]. The aim of the current study
was therefore to test the hypothesis that elevated levels of glucose and
reactive aldehydes, and pre-glycated proteins (generated by glucose
and reactive aldehydes) may modulate the activity of the proteasome
system, as this systemappears to play an essential role in degradation of
these modiﬁed proteins [1].1. Materials and methods
1.1. Materials
Proteasomal enzyme activity was quantiﬁed using the pro-ﬂuores-
cent peptides N-Suc-Leu-Leu-Val-Tyr-AMC (chymotrypsin-like activi-
ty), and Boc-Leu-Ser-Thr-Arg-AMC (trypsin-like activity) purchased
from Sigma-Aldrich (Castle Hill, NSW, Australia). Caspase-like activity
was examined using Ac-Nle-Pro-Nle-Asp-AMC (Auspep, Parkville, VIC,
Australia). All substrates were prepared as 100× stocks in DMSO
(10 mM for chymotrypsin and caspase substrates, 60 mM for trypsin)
[21] and stored at−20 °C. Glucose and sodium dihydrogen orthophos-
phate monohydrate (NaH2PO4·H2O) were obtained from Merck
(Kilsyth, VIC, Australia), digitonin from Calbiochem (La Jolla, CA, USA),
disodiumhydrogen orthophosphate dodecahydrate (Na2HPO4·12H2O)
fromUnivar (SevenHills,NSW,Australia), dithiothreitolwas fromAstral
Scientiﬁc (Gymea, NSW, Australia), and Tris hydrochloride from
Amresco (Solon, OH, USA). All other chemicals were obtained from
Sigma-Aldrich (Castle Hill, NSW, Australia) unless otherwise noted. All
solutions were prepared using nanopure water (Milli Q system,
Millipore-Waters, Lane Cove, NSW, Australia) and treated with washed
Chelex-100 resin (Bio-Rad, Regents Park, NSW, Australia) to remove
trace metal ions.1.2. Preparation of glycated BSA
Extensively glycated BSA was prepared by incubation of BSA
(50 mg mL−1) with D-glucose (1 M) in 200 mM phosphate buffer (0.2
M Na2HPO4·12H2O and NaH2PO4·H2O, pH 7.4, pre-treated with
Chelex 100 resin to remove trace metal ions) at 37 °C for 8 weeks
under sterile conditions and an atmosphere of humidiﬁed 5% CO2.
Control BSA samples were incubated in a similar manner in the
absence of glucose [7]. BSA modiﬁed by methylglyoxal (MGO),
glycolaldehyde (GA) or glucose was generated by incubating BSA
(80 mg mL−1) with MGO or glucose at 10 and 200 mM, or GA at
10 mM, for 17 h at 37 °C in 50 mM phosphate buffer (pH 7.4). Control
BSA was incubated in a similar manner in the absence of MGO, GA or
glucose. Immediately after incubation, protein samples were passed
through 2 successive PD10 columns (Amersham Bioscience, Castle
Hill, NSW, Australia) using chelexed-treated 50 mMphosphate buffer,
pH 7.4, as the eluting buffer to remove unbound MGO, GA or glucose.
With the exception of BSA incubatedwith glucose for 17 hwhere little
adduction occurs, these incubations result in the formation of BSA
with multiple covalently-bound sugar molecules or aldehyde groups
[25–27] (see also below). Protein concentrations were determined
using the Pierce (Rockford, IL, USA) bicinchoninic acid (BCA) assay
with commercial BSA used as a standard [28].
1.3. Characterization of glycated BSA
The nature and extent of BSA glycation was assessed for each
condition by HCl hydrolysis of triplicate samples as described
previously [29], with modiﬁcations according to Zeng and Davies
[30]. Brieﬂy, vials containing 0.4 mg of protein were placed in Pico-
Tag reaction vials (Alltech, Baulkham Hills, NSW, Australia) contain-
ing 1 mL of 6 M HCl and 50 μL of thioglycolic acid. The reaction vials
were subsequently evacuated and ﬂushed with nitrogen gas three
times, before hydrolysis under vacuum for 17h at 110 °C. Following
drying down using a vacuum concentrator (Christ RVC 2-33; John
Morris Scientiﬁc, Chatswood, NSW, Australia), samples were resus-
pended in 400 μL of 0.2 M borate buffer, pH 9.0, and ﬁltered through
0.2 μm centrifugal ﬁlter units (Pall Nanosep MF; 500 μL capacity).
Samples were kept at 4 °C prior to HPLC analysis.
Separation and quantiﬁcation of AGEs was carried out by gradient
HPLC using a Shimadzu HPLC system (Shimadzu Oceania, Rydalmere,
NSW, Australia) consisting of a SIL-10ADVP auto injector (capable of
pre-column derivatization), two LC-10ATVP pumps, DGU-20A3 degas-
ser, SCL-10-10AVP system controller, CTO-10ASVP column oven (set at
30 °C) and RF-10AXL ﬂuorescence detector. The column used was a
Beckman Coulter Ultrasphere ODS column (250×4.6 mm, 5 μm pore
size) with corresponding guard column (45×4.6 mm). Buffer A was
composed of 4.8% (v/v) 1 M sodium acetate pH 6.5 in water, 4% (v/v)
methanol, and water, whilst buffer B consisted of 100% methanol. A
solvent gradient was utilized at 1 mL/min, which consisted of 15%
buffer B for 40 min, 15–37% B over 36 min, 37–90% B over 2 min, 90% B
for 7 min, 90–5% B over 1 min, and re-equilibration at 15% B for 9 min
(total run time 95 min).
AGEs were quantiﬁed using authentic standards, which were used
to construct standard curves over the range of 0–100 pmol per
injection: Nε-carboxymethyllysine (CML; Sigma); Nε-carboxyethylly-
sine (CEL; Toronto Research Chemicals); (2S)-2-amino-5-(5-methyl-
4-oxo-4,5-dihydro-1H-imidazol-2-ylamino)-pentanoic acid (MG-H1;
PolyPeptide Laboratories); (2S)-2-amino-5-(2-amino-5-methyl-4-
oxo-4,5-dihydro-imidazol-1-yl)-pentanoic acid (MG-H2; two isomers
can be detected for this product, designated 2a and 2b; PolyPeptide
Laboratories). One minute prior to injection, 40 μL of each sample/
standard was derivatized by the addition and mixing of 20 μL of o-
phthaldialdehyde (OPA) containing 0.5% (v/v) 2-mercaptoethanol.
Forty microliters of each sample was injected, and 30 μL of each
standard. The ﬂuorescent derivatives were detected by ﬂuorescence
Fig. 1. Effect of free glucose on proteasomal enzyme activities in J774A.1 cell extracts.
Cell extracts were incubated with glucose (0, 5 or 20 mM) for 5 min at 21 °C. Then the
chymotrypsin-, caspase- or trypsin-like activities were assessed and analysed as
described in the Materials and methods. White, grey and black bars represent
proteasomal activity of cell extracts incubated with 0, 5 and 20 mM glucose,
respectively. *Pb0.05 compared to 0 mM glucose condition using one-way ANOVA
and Newman–Keuls multiple comparison test. Data are mean±SEM of three or more
experiments.
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to ensure that all analytes were within the range of the relevant
standard curves. Limits of detection for the AGEs were approx.
0.2 nmol AGE per mg of protein. All samples were standardized to
their Gly content, as quantiﬁed by HPLC, thus serving as their own
internal standards. Samples were diluted 100-fold with water, and
separated using the same HPLC system and pre-column derivatization
as for AGE detection, but with different buffers and gradient. Buffer A
consisted of 20% (v/v) methanol, 5% (v/v) tetrahydrofuran, 10%
aqueous 1 M sodium acetate pH 5.0, and water; buffer B was identical
except it contained 80% (v/v) methanol in place of the 20% (v/v)
methanol in buffer A. The following gradient was used: 5% B for 7 min,
5–25% B over 10 min, 25–50% B over 10 min, 50% B for 8 min, 50–100%
B over 5 min, 100% B for 5 min, 100–5% B over 1 min, and re-
equilibration at 5% B for 9 min (total run time 54 min). Fifteen
microliters of each derivatized sample/standard was injected. The
standards used were commercial products (Sigma), with standard
curves prepared over the range 0–50 pmol per injection; this also
allowed quantiﬁcation of Arg in each sample.
1.4. Cell culture
J774A.1mousemacrophage-like cells (TIB-67, ATCC,Manassas, VA,
USA)were grown in 175 cm2 Falcon ﬂasks (Becton Dickinson, Franklin
Lakes, NJ, USA) in Dulbecco's modiﬁed Eagle's medium (DMEM) with
added heat-inactivated foetal calf serum (FCS) (10% (v/v); JRH
Biosciences, Lenexa, Kansas, USA), 2 mM L-glutamine (Thermo
Electron, Melbourne, VIC, Australia) and penicillin/streptomycin
(100 U mL−1 and 0.1 mg mL−1, respectively; BioWhittaker (Lonza,
Walkersville, MD, USA)). Cells were harvested by scraping using a
disposable cell scraper (Greiner Bio-One, Frickenhausen, Germany)
and the cell suspension replated at 1:16 dilution every 3–4 days. Cell
extracts for proteasome measurement activity, were prepared from
conﬂuent cultures of J774A.1 cells contained in 75 cm2 Falcon ﬂasks.
The media was replaced with cold PBS, the cells removed by scraping,
and subsequently washed three times in cold PBS by centrifugation
(Beckman, Palo Alto, CA, USA) at 524 g for 5 min at 4 °C. Cell pellets
were snap frozen in liquid nitrogen and stored at−80 °C.
1.5. Preparation of cell extracts for proteasome activity measurement
Cell extracts containing proteasomes were prepared as described
previously [21]. Brieﬂy, cell pellets were resuspended in 500 µL of
homogenisation buffer (50 mM Tris–HCl, pH 7.5, 250 mM sucrose,
5 mM MgCl2, 2 mM ATP, 1 mM DTT and 0.5 mM EDTA) containing
0.025% (w/v) digitonin. ATP was employed to prevent dissociation of
the 26S proteasome into its components and to ensure that 26S, and
not 20S activity, was measured [21]. Resuspended cells were
incubated on ice for 5 min to allow permeabilisation by digitonin,
and were then transferred to glass tubes (8×34 mm; Beckman, Palo
Alto, CA, USA). The cytosol was forced out by centrifugation at
20,000g for 15 min at 4 °C using a Beckman centrifuge (120/1, Palo
Alto, CA, USA). The optimal protein concentration for the proteasome
activity assay was determined to be 11–12 µg protein/reaction, with
dilutions made using homogenisation buffer.
1.6. Treatment of cell extracts with free aldehydes, glucose and
glycated BSA
The effect of aldehydes and glucose on proteasome activity, was
examined using cell extracts incubated with MGO (0.25, 0.5, 1, 10 and
20 mM), GO or GA (1, 10 and 20 mM) at 21 °C for 5 min. Free glucose
(5 and 20 mM) was investigated in a similar manner. The effects of
glycated BSA on proteasome activity were examined using 0.4, 1 or
4 mg mL−1 pre-glycated BSA prepared as described above.1.7. Proteolytic activity measurement and analysis
Immediately after completion of the incubations with the required
materials (free aldehyde, glycated BSA, epoxomicin, or no additives),
proteolysis was measured by a continuous assay of peptidase activity
using ﬂuorescence detection [21]. Samples were prepared in reaction
buffer (50 mM Tris–HCl, pH 7.5, 40 mM KCl, 5 mM MgCl2, 0.5 mM
ATP, 1 mM DTT, 0.5 mg/mL BSA) with 100 µM for the chymotryptic
and caspase substrates, or 600 µM tryptic substrate. Fluorescence (λex
360 nm, λem 460 nm) was measured using a Cytoﬂuor II plate reader
every minute for 30 min. Potential contributions from non-proteaso-
mal enzyme activity were examined using the proteasome-speciﬁc
inhibitor epoxomicin with proteosome activity considered to be the
fraction of ﬂuorescence increase that was sensitive to this agent;
ﬂuorescent change due to proteasomal activity were therefore
calculated as the difference in the rate of ﬂuorescence change over
time (ΔFU/min) between determinations made in the presence (pre-
incubation with 20 µM reagent at 21 °C for 30 min) and absence of
this agent [21].
1.8. Statistical analyses
Data from all enzymatic activity measurements are expressed as
mean±SEM from 3 or more separate experiments, each assayed in
triplicate. HPLC samples were analysed from triplicate experiments.
Statistics analysis was performed using Prism 4.03 (GraphPad
software, San Diego, CA, USA). For pair comparisons, paired t-tests
were employed. For multiple comparisons, one-way analysis of
variance (ANOVA) with Newman–Keuls Multiple Comparison test
was employed. For the AGE and amino acid analyses one-tailed
unpaired t-tests were employed comparing the glycated BSA samples
to the corresponding control. Results were considered statistically
signiﬁcant at the Pb0.05 level.
2. Results
2.1. Effect of glucose on proteasomal enzyme activities in J774A.1
cell extracts
Incubation of cell extracts with 5 or 20 mM glucose at 21 °C for
5 min had no effect on chymotrypsin- and trypsin-like activities as
compared with glucose-free controls, although a dose-dependent
trend towards an enhancement in activity was observed (Fig. 1). With
20 mM glucose a signiﬁcant increase (ca. 1.5-fold) in caspase-like
activity was observed compared to the no glucose condition, but this
was not signiﬁcant when compared to the 5 mM glucose system.
Fig. 2. Free reactive aldehydes enhance proteasomal enzyme activities. Cell extracts
were incubated with GA and GO (0, 1, 10 and 20 mM), and MGO (0, 0.25, 0.5, 1, 10 and
20 mM) for 5 min at 21 °C. The (A) chymotrypsin-, (B) caspase-, and (C) trypsin-like
activities were measured as described in the Materials and methods. White bars
represent control, dotted bars show 0.25 mM (MGO, trypsin-like activity only), cross
hatched bars represent 0.5 mM (MGO, trypsin-like activity only), grey bars show 1 mM,
black bars represent 10 mM and hatched bars represent 20 mM treatments. *Pb0.05 or
#Pb0.05 for results compared to control or to other treatments, respectively, using one-
way ANOVA and Newman–Keuls multiple comparison test. Data are mean±SEM of
three or more experiments.
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J774A.1 cell extracts
The effect of reactive aldehydes on the proteasomal enzyme
activities were investigated by incubation of cell extracts of J774A.1
cells with GA, GO or MGO over the concentration range 0.25–20 mM,
at 21 °C for 5 min. Proteasomal activities were then quantiﬁed as
described above. Treatment of the proteasomal preparations with all
three reactive aldehydes resulted in a dose-dependent increase in
chymotrypsin-like activity (Fig. 2A). This increase was statistically
signiﬁcant at 10 mM for each aldehyde. However, at the highest
concentration examined there was attenuation in activity found with
GA treatment, whereas no further increasewas observedwith GO, and
the activity was further enhanced with MGO. Thus the chymotrypsin-
like activity of the cell extracts of J774A.1 cells differentially
responsive to MGO, GO and GA.
Differences in the response to aldehyde treatment were also
observed with the caspase-like activity (Fig. 2B). This activity was
relatively insensitive to MGO treatment with the exception of the
highest concentration examined. In the cases of GA- and GO-
treatment, a dose-dependent enhancement in caspase-like activity
was apparent with a signiﬁcant increase detected at 10 mM.
Interestingly, a trend towards a suppression of caspase-like activity
was observed at very high aldehyde levels (20 mM GO, 10 mMMGO)
when compared to control, but this did not reach statistical
signiﬁcance.
Trypsin-like activity was signiﬁcantly modulated by MGO at
0.5 mM and above, resulting in a signiﬁcant enhancement of activity,
with this stimulation being concentration-dependent (Fig. 2C). In
contrast, GO and GA only increased trypsin-like activity at high
concentrations (10 and 20 mM for GA and GO, respectively).
2.3. Characterization of BSA modiﬁcation by glucose and reactive
aldehydes
Modiﬁcation of the glycated and control BSA was characterized by
HPLC analysis. Incubation of BSA with 200 mM MGO resulted in the
detection of signiﬁcant levels of the AGEs CML, CEL, MG-H1, MG-H2a
and MG-H2b (Fig. 3) and 58% loss of parent Arg (Fig. 3). Lys residues
were also depleted but this was not quantiﬁed (see below). Signiﬁcant
Arg modiﬁcation was also evident upon incubation with 10 mMMGO,
as evidenced by elevated levels of CML, MG-H1, MG-H2a and MG-
H2b, and loss of 23% of the parent Arg (Fig. 3). Reaction at Lys residues
was less marked in this case as judged by the extent of CEL formation
(Fig. 3). With GA as the modifying agents, elevated levels of CMLwere
detected together with a small, but signiﬁcant, loss of Arg (Fig. 3).
Incubation of BSA with glucose for 8 weeks resulted in the
formation of very high levels of CML (over 30-fold greater than
10 mM GA, and over 300-fold greater than MGO), as well as
signiﬁcant amounts of CEL. A signiﬁcant (22%) loss of Arg was also
detected, which is not accounted for by the concentration of AGEs
detected by HPLC, consistent with the formation of additional
products such as Nω-carboxymethylarginine (CMA), which is known
to be formed upon incubation of protein with glucose for prolonged
periods, but which is susceptible to acid hydrolysis [31]. Parent Lys
was also depleted in these samples consistent with the formation of
Lys-derived AGEs (CML, CEL), but this was not quantiﬁed absolutely,
due to variability in Lys derivatization by OPA. No signiﬁcant AGE
formation, or parent Arg, was observed upon incubation of BSA with
10 mM or 200 mM glucose for 17 h (Fig. 3).
2.4. Effects of native and glycated proteins on proteasomal enzyme
activity
The effects of the glycated and control BSA on proteasome activity
were examined by incubating J774A.1 cell extracts with threedifferent concentrations of native or modiﬁed protein (0.4, 1 and
4 mg protein mL−1) for 5 min at 21 °C. Initial studies examined
control (native) incubated BSA (Fig. 4). Chymotrypsin activity was
sensitive to inhibition by the highest concentration of BSA incubated
overnight, or for up to 8 weeks at 37 °C (Fig. 4A). Caspase-like activity
was decreased signiﬁcantly on incubation with the highest concen-
tration of native BSA incubated for 8 weeks, but not at shorter times or
with lower concentrations (Fig. 4B). Trypsin-like activity was
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were made versus the corresponding samples incubated with native
BSA for the same period.
BSA pre-glycated with glucose for 17 h had no signiﬁcant effects
on proteasomal activity compared to the incubated protein control
(data not shown). In contrast, BSA glycated by incubation with 1 M
glucose for 8 weeks, gave rise to a signiﬁcant inhibition of both the
chymotrypsin- and caspase-like activities at the highest concentration
of BSA used compared to the incubated protein control. The trypsin-
like activity was not affected (Fig. 5). With the highest protein
concentration (4 mg/mL) an apparent negative gradient was ob-
served; this arises from the subtraction of the ﬂuorescence changes
observed with the epoxomicin controls from the glycated protein
data, and is believed to reﬂect inhibitory effects of the native or
glycated BSA on other proteolytic systems present in the cell extracts
(e.g. calpains and lysosomal cathepsins) [21].
No signiﬁcant inhibitory effects on the trypsin-like activity of the
proteasomal extracts was observed with BSA pre-glycated with
glucose over the range of BSA and glucose concentrations, and
glycation conditions, examined (Fig. 5). In contrast to the other
activities (see above) a signiﬁcant increase in trypsin-like activity was
observed with the highest concentration of BSA modiﬁed with either
10 mM or 200 mM glucose for 17 h (Fig. 5F).
The effects of BSA glycated by reactive aldehydes on proteasomal
enzyme activities were examined in a similar manner to that outlined
above, with the BSA (0.4, 1 or 4 mg protein mL−1) pre-incubated
10 mM GA (GA (10 mM)-BSA), 10 or 200 mM MGO (MGO (10 mM)-
BSA and MGO (200 mM)-BSA, respectively) for 5 min at 21 °C. Whilst
low concentrations of GA-modiﬁed BSA (0.4 (data not shown) and
1 mg protein mL−1) had no signiﬁcant effects upon any of the
proteasomal activities, high concentrations of this material (4 mg
protein mL−1) signiﬁcantly inhibited both the chymotrypsin- and
caspase-like activities (Fig. 6A–D). In contrast, this material stimulat-
ed trypsin-like activity (Fig. 6E–F). BSA modiﬁed with10 mM MGO
had no effect upon any of the measured proteasomal activities at any
of the protein levels examined. With BSA modiﬁed with 200 mM
MGO, an inhibition of caspase-like activity was observed at all the
protein concentrations examined (Fig. 6C–D). In addition, inhibition
of both the chymotrypsin and trypsin activities were detected with
the highest concentrations (4 mg protein mL−1) of this modiﬁed
protein (Fig. 6B and F).
3. Discussion
This study has examined the effects of short-term exposure to
glucose, reactive aldehydes and pre-glycated proteins on the activities
of one of the major components of the intracellular protein removal
systems, the proteasome. One of the deﬁning features of diabetes is
hyperglycaemia, with elevation of blood glucose levels from 5 mM to
up to ca. 30 mM in extreme cases [32]. This elevation in glucose is
associated with elevations in the levels of reactive aldehydes derived
from glucose and other metabolic processes, and the generation of
glycated/glycoxidized proteins [32]. Elevated levels of these materialsFig. 3. Characterization of AGE formation and parent amino acid loss on glycated BSA
samples. Control and glycated BSA samples, prepared as indicated in the text, were
analysed by HPLC after ﬂuorescent tagging. Concentrations were determined by
comparison with authentic standards of AGE or parent amino acids derivatized under
identical conditions. Data for AGE are expressed as millimoles of product relative to
moles of parent Gly, an amino acid not expected to be modiﬁed by glycation; this
comparative measure accounts for any protein loss during processing. Values for
control BSA samples taken through identical protocols have been subtracted from the
treatment data; in all cases these control data were typically b0.2 mmol AGE/mol Gly.
Data for parent amino acid are expressed as a % of the levels detected in control BSA.
Absolute levels of the amino acids quantiﬁed were in agreement with the expected
amino acid composition from protein databases. Data are mean±SD for triplicate
determinations from separate experiments. *Pb0.05 relative to the corresponding BSA
control for each condition, using 2-tailed unpaired t-tests.
Fig. 4. Effect of native incubated BSA on proteasomal enzyme activities of J774A.1 cell
extracts. White, black and grey columns represent 5 min incubation of cell extracts at
21 °C with 0, 1 and 4 mg/mL of control BSA that was incubated for 17 h or 8 weeks.
Proteasomal enzyme activities of J774A.1 cell extracts after treatment were determined
using (A) chymotryptic, (B) caspase or (C) tryptic substrate and measurement of
speciﬁc activities as described in the Materials and methods. *Pb0.05, using one-way
ANOVA and Newman–Keuls multiple comparison test to relevant control. Each column
represents mean±SEM of 3 or more experiments.
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extent and duration of disease [33–37]. Thus increases in the level of
glycated haemoglobin, a commonly used marker of hyperglycaemia,
have been shown to both correlate with, and predict future
cardiovascular disease [35–37]. The effects of these materials on
proteasome function have been studied here in cell extracts from a
macrophage-like cell line, as such cells play a key role in the
development of atherosclerosis — the major macrovascular compli-cation of diabetes, and the most important contributing factor to
mortality and morbidity in people with diabetes [38]. Partially-
puriﬁed cell extracts were used in these studies as modulation of the
proteasomal system in intact cells by these agents is difﬁcult to assess
without accompanying perturbation of other aspects of cell metab-
olism. In their role as scavenging cells of the immune system,
macrophages are likely to be exposed to glycated proteins as well as
elevated glucose and reactive aldehydes [6,39]. However the effects of
glucose, reactive aldehydes and glycated proteins upon cellular
metabolism and proteasomal function are not yet fully understood,
though there is considerable current interest in this area, with
previous studies having examined, for example, the rates of
degradation of glycated/glycoxidized proteins in other cell types
and tissues [3,22,40–42], and the effect of reactive aldehydes and
glycated proteins on the other major proteolytic system of cells, the
endo-lysosomal system (e.g. [3,7,43]).
The data reported here demonstrate that the effects of glucose,
reactive aldehydes and glycated proteins on the three major activities
of the proteasome are diverse and complex, with both stimulation
and inhibition detected under different conditions. The data obtained
indicate that free reactive aldehydes induce more pronounced effects
on proteasomal enzyme activities than glucose itself under the same
conditions. This is consistent with previous data that have indicated
that reactive aldehydes are considerably more reactive (up to 20,000-
fold) than glucose itself [15,25], though these aldehydes are present
at much lower levels (see below). Glucose is the most abundant, but
is also considered to be the least deleterious of the common sugars
present in humans [3]. In vivo studies have suggested that elevated
levels of glucose alone are insufﬁcient to accelerate diabetes-
associated atherosclerosis [44]. The results of the current study are
also consistent with previous studies that have reported that elevated
levels of glucose did not inhibit some cytosolic (e.g. glyceraldehyde-
3-phosphate dehydrogenase and glutathione reductase) and lyso-
somal enzymes (e.g. the cysteine-dependent cathepsins, B and L), in
vitro, whereas reactive aldehydes showed marked inhibitory effects
[7,23].
In contrast to these previous reports of enzyme inhibition induced
by reactive aldehydes (see above), the major effect observed in the
current study was a stimulation of proteasomal enzymatic activity. A
similar enhancement of nuclear proteasomal activity has been
detected in intact cells treated with GO [45], though the exact
mechanism by which this occurs has not been identiﬁed. A number of
treatments, such as incubation with basic polypeptides, SDS and fatty
acids have previously been shown to activate the 20S proteasome by a
mechanism that involves changes in protein conformation [20]. Thus
alterations in the conformation of the β subunits have been proposed
to enhance catalytic activity, and changes in the α ring may facilitate
substrate entry to the catalytic core [20]. In the case of the 26S
proteasome examined here, reactive aldehyde-induced alteration to
either the lid or base of the 19S proteasome that delivers substrates to
the proteolytic core may also play a role. As the species used to assess
enzymatic activity in the current study were small peptides, rather
than large proteins, changes in the conformation of the β subunits
may be themost likely cause of the observed stimulation of activity, as
the entry of these (unstructured/unfolded) peptides into the protein
core are less likely to be affected by steric factors, though this
obviously requires further study. It has also been reported that post-
translational modiﬁcations of the proteasome complex (or its
subunits) including phosphorylation and acetylation, can modulate
proteasomal activities [19,46,47]. Thus phosphorylation of the α
subunits appears to enhance activity of the proteasome inmammalian
cells, possibly by inducing conformational changes that modulate
substrate accessibility [46]. Modiﬁcation of speciﬁc Arg or Lys residues
on proteasomal subunits by the reactive aldehydes under study (cf.
data in Fig. 3) may induce similar conformation changes, and it is
therefore of interest to note that enhanced levels of glycated (Nε-
Fig. 5. Effect of BSA, pre-glycated with glucose, on proteasomal enzyme activity of J774A.1 cell extracts. BSA was pre-glycated with 10 or 200 mM glucose for 17 h or 1 M glucose for
8 weeks as described in Materials and methods. White and grey bars represent control BSA and BSA glycated with glucose, respectively. Cell extracts were incubated with 1 mg/mL
(A, C and E) or 4 mg/mL (B, D and F) of glycated BSA or control BSA for 5 min at 21 °C, then the speciﬁc proteasome substrate was added and the activities were measured as
described in the text. *Pb0.05, using two-tailed paired t-tests. Each column represents mean±SEM of 3 experiments.
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detected in aging cells [48]. In contrast, acetylation of the N-terminal
Thr residue of the active β subunits and the α subunits results in
inactivation of 20S proteasome [19,47]. A number of oxidants have
also been shown to alter proteasome activity, with both inhibition
[49,50] and activation reported [51]. Upregulation of proteasome
activity may be of considerable biological relevance in light of the key
role that this complex plays in the degradation of inhibitory proteins,
such as IκB, which prevents NF-κB activation and signalling [52], as
has been reported in atherosclerotic plaques from people with
diabetes [53].
The data reported here are in contrast to a previous study that
reported an inhibitory effect of GO on proteasomal enzyme activities
in vitro [22]. There are however, a number of signiﬁcant differences
between these two studies, with this previous investigation showing
that GO inhibited the 20S proteasome puriﬁed from human placenta
after a 30 min incubation period [22]; this preparation lacks the
regulatory subunits present on the 26S form, and hence effects of thereactive aldehydes on substrate accessibility and the control of this
process, would not have been detectable in this earlier study. The 20S
form of the proteasome was not examined in the current study, as the
majority of protein turnover in eukaryotic cells appears to occur via
the 26S complex [21,54]. Furthermore, whilst the short incubation
times employed in the current study may be sufﬁcient to alter the
conformational structure of the 26S complex in such a way as to allow
greater substrate accessibility and thus enhanced activity, the longer
incubation times, used by Bulteau et al. [22], may result in the
accumulation of more severe damage to the 20S core and a
suppression of enzyme activity.
In contrast to the absence of effects induced by free glucose,
signiﬁcant changes in activity were detected with BSA pre-treated
with glucose. With low (pathologically-relevant) concentrations of
glucose (10 mM, 17 h), and short incubation times with high glucose
(200 mM glucose, 17 h), a small but signiﬁcant stimulation of the
trypsin-like activity was detected with the highest concentrations of
glycated protein examined. However with heavily glycated BSA (1 M
Fig. 6. Effects of BSA pre-glycated with reactive aldehydes on proteasomal enzyme activities of J774A.1 cell extracts. Cell extracts were incubated with 1 mg/mL (A, C and E) or 4 mg/
mL (B, D and F) of control BSA, or BSA modiﬁed using 10 mMGA, 10 mMMGO or 200 mMMGO, for 5 min at 21 °C. Chymotrypsin-, caspase- or trypsin-like activity was measured as
described in Materials and methods. White and grey bars represent control BSA and modiﬁed BSA by reactive aldehydes, respectively. *Pb0.05, using a two-tailed paired t-test
relative to the corresponding control BSA. Each column represents mean±SEM of three experiments.
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caspase-like activities were observed and the stimulation of trypsin-
like activity was reversed.With the short incubation times (17 h) only
low levels of early (reversible) glycated adducts would be expected to
be formed with glucose (10 and 200 mM), as a chemical relaxation
time of about 2.5 h has been reported for glucose and human serum
albumin (HSA) in blood plasma to give the Schiff's base under
physiological conditions [55]. This low level of modiﬁcation has been
conﬁrmed here (Fig. 3). Subsequent rearrangement of this species to
fructosamine or an Amadori product occurs over a much longer time-
scale with equilibrium reached by ca. 38 h [55]. Thus it would appear
that the formation of low levels of early (reversible) adducts on BSA
do not signiﬁcantly inhibit proteasomal enzymatic activities, whereas
the advanced glycation products that are formed in high yield as a
consequence of very high glucose concentrations and long-term
incubation (Fig. 3), have marked inhibitory effects. An absence of
marked inhibitory effects with the combination of BSA and short-term
glucose incubation has also been reported for lysosomal cysteine-
dependent cathepsins [7]. The inhibition observed with high glucose/
long-term incubation are consistent with those of Stolzing et al. [41]
for isolated 20S proteasomes where inhibition of the chymotrypsin-,
caspase- and trypsin-like activities was observed on incubation with
AGE-BSA (produced by incubation of BSA with 0.25 and 1 M glucose
for 6 weeks) for 1 h. In both the current study and this previous work
[41] the caspase-like activity appears to be the most markedlyaffected, and it is clear from the current data that this inhibition is
rapid and can occur in b5 min.
Reactive aldehydes are known to be generated during glucose
degradation (e.g. over a 3 week period at pH 7.4 and 37 °C), and that
the presence of proteins, such as HSA, enhances their rate of formation
[55]. Elevated levels of these aldehydes have also been detected in
human plasma from people with diabetes compared to healthy
controls, though there is considerable variation in the reported values
[56–58]. The high reactivity of these aldehydes [55] with nucleophilic
sites present on proteins (primarily Arg, Lys, His and Cys side-chains
and the N-terminal amino group), limits the concentration of these
materials in plasma, and these values represent steady-state con-
centrations at the time of sampling, rather than the overall ﬂuxes of
modifying agent to which a protein may be exposed over its lifetime.
Whether these plasma levels reﬂect those present within cells is also
unclear, and no speciﬁc measurements have been reported for cells.
As many of the metabolic processes that generate reactive aldehydes
are intracellular (e.g. decomposition of triose phosphates [13]) it is
likely that cellular levels will be higher than those detected in plasma
where the levels may reﬂect primarily glucose auto-oxidation and
efﬂux of the reactive aldehydes from cells. Higher ﬂuxes might also be
expected at sites of inﬂammation (e.g. within the artery wall during
the development of atherosclerosis) as a result of the localisation of
enzymes that can generate reactive aldehydes at such sites (e.g.
myeloperoxidase which generates GO and MGO from the amino acids
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products of myeloperoxidase-mediated reactions accumulate on
proteins to much higher levels in atherosclerotic lesions than are
present in plasma/serum (up to 8-fold greater for apolipoprotein A-I,
ca. 100-fold for apolipoprotein B-100 and ca. 115-fold for total protein
[59,60]). In addition it is well established that there is a marked
accumulation of lipid oxidation products, another potential source of
reactive aldehydes, in atherosclerotic lesions, with these levels
massively exceeding those in plasma [61]. These data suggest that
higher levels of reactive aldehydes are likely to be present in
atherosclerotic lesion and surrounding tissue, than might be detected
in plasma. Thus measurements of steady-state levels of reactive
aldehydes in plasma, may provide very limited information on the
overall ﬂuxes of reactive aldehydes to which proteins may be exposed
within cells and tissues, and particularly at the sites of developing
micro- and macrovascular complications in diabetes.
In the light of the above discussion, it is possible that the inhibitory
effects observed with highly glycated BSA on the chymotrypsin- and
caspase-like activities of the proteasome may arise from reactions of
reactive aldehydes formed from glucose over the extended incubation
period, rather than from direct glucose reactions (cf. the elevated
levels of CML and CEL detected on the BSA incubated with glucose for
8 weeks). This conclusion is consistent with the observed inhibitory
effect of BSA pre-glycated with the aldehydes (as opposed to the
stimulation detected with the free aldehydes themselves), with this
inhibition being most evident with the caspase- and chymotrypsin-
like activities. Thus inhibition of both activities was detected with
4 mg mL−1 of BSA pre-glycated with 10 mM GA (in contrast to a
stimulation of trypsin-like activity). In contrast, with the same
concentrations of MGO, no signiﬁcant changes in activity were
detected, though inhibition was again seen (with all three activities)
with higher concentrations of MGO. These data suggest that the
species generated by GA, such as CML (cf. Fig. 3) have a greater
inhibitory effect than those generated by MGO (CEL and MG-H1/2),
thoughwhether this is a manifestation of the nature of these products,
or their relative yields is unclear. These inhibitory effects of pre-
glycated proteins mirror the suppressive effects of similar species on
the activity of lysosomal cathepsins [7,62].
Previous studies have shown that incubation of MGOwith BSA at a
molar ratio of 10:1 results in a rapid increase in both irreversible and
reversible binding of MGO to BSA and a rapid decrease in free MGO
over 24 h [15]. The major sites of irreversible adduction under these
conditions are Arg residues with these yielding imidazolones
including MG-H1 and MG-H2a/b [15]. Incubation of GA with BSA at
a molar ratio of 200:1, results in modiﬁcation of Lys residues and
generates C-2-imine cross-links and CML, with the maximum
formation of these products detected after ca. 30 min [63]; these
data are consistent with the results obtained in the current study (cf.
Fig. 3), where the molar ratios of aldehyde:BSA were 8, 166 and 8 for
the 10 and 200 mMMGO, and 10 mM GA conditions respectively. The
AGE products formed on the BSA may be responsible for the observed
inhibition of enzymatic activity, though it is also possible that this
arises from loss of the parent amino acid side-chains. Whether, and
exactly which, AGE species is/are responsible for inhibition, cannot be
discerned from the present data due to the difﬁculty in generating
speciﬁc individual modiﬁcations, in isolation, on this protein.
However it is clear from the data obtained that the extent of
proteasomal enzyme alteration by glycated proteins varies with: (1)
the total amount of glycated proteins that the proteasomal prepara-
tions are exposed to, (2) the nature of the glycating agent, (3) the
extent of glycation at a ﬁxed incubation time and protein concentra-
tion, and (4) the nature of proteasomal active site, with the sensitivity
to inhibition typically following the order caspase-likeNchymotryp-
sin-likeN trypsin-like.
The mechanism of inhibition may be any of the following: (1)
glycation may result in the formation of protein cross-links and AGEthat stabilize the BSA structure [18,22,64] resulting in a slower rate of
degradation by 26S proteasome, and hence slower cleavage of the
peptide used to assess enzyme activity as a result of competition for
active sites [22]; (2) the glycated BSA may react, or form an adduct,
with the nucleophilic oxygen of the Thr-1 residues in the β-type
subunits [65] thereby inhibiting activity; (3) the AGE (or oxidation)
products may modulate the structure or function of the α ring of
catalytic core that facilitates the substrate entry [2,65] with this
resulting in reduced access of the peptide substrate and hence a
reduced rate of cleavage; or (4) the glycated protein may modulate
(or block) the activity of 19S regulatory subunits, that control the
access of substrates to the core [65]. Which of these mechanisms are
operative in the current study cannot be determined from the current
data, and further studies are required to elucidate this point.
One imitation of the current investigation is the use of cell extracts
that contain the proteasome, rather than highly puriﬁed preparations.
The former were employed due to difﬁculties in isolating sufﬁcient
active 26S complex from cells, without signiﬁcant inactivation and/or
loss of the 19S subunits that would compromise data analysis.
However the cruder cell extracts are likely to contain other non-
proteasomal proteases, such as calpains and possibly lysosomal
cathepsins [21]. Possible contributions of these non-proteasomal
enzymes to the observed proteolytic activity was minimised by
quantifying activity at pH 7.4, where most lysosomal enzymes show
little activity [21], and by including parallel epoxomicin-treated
samples. Subtraction of residual activity obtained in the presence of
this speciﬁc proteasomal inhibitor [66], from the total activity,
provided data that has been ascribed to the proteasome [21].
However, in some experiments this resulted in an apparent “negative”
activity which is consistent with the glucose/free aldehyde or
glycated proteins also inhibiting non-proteasomal activity in the
samples, resulting in activities lower than those of the epoxomicin
controls. Potential circumvention of this effect by either pre- or post-
treating the incubations with epoxomicin was considered but not
attempted as this would result in different overall incubation periods
and potentially misleading data. Blockade of other contributing
proteolytic activities by use of inhibitors was not attempted due to
the diverse and unknown nature of all of these activities and the non-
availability of speciﬁc inhibitors.
In conclusion, glycated proteins generated by either reactive
aldehydes or long-term exposure to high glucose concentrations has
been shown to inhibit the chymotrypsin-, caspase- and to a lesser
extent the trypsin-like activities of proteasomal fractions from
J774A.1 cells. This suppression of proteasome activity by glycated
proteins, in conjunction with the previously reported inhibition of
lysosomal cathepsin enzymes by the same species [7] may contribute
to the intracellular accumulation of glycated and otherwise damaged
proteins in people with diabetes. A decreased rate of intracellular
catabolism of these glycated proteins is likely to result in a higher
concentration (accumulation) and increased residence time of these
materials within cells resulting in an enhanced level of further
secondary reactions and advanced glycation products. A longer half-
life for these modiﬁed proteins within cells would also be expected to
increase the likelihood of protein cross-linking and aggregation, with
deleterious consequences on cellular function, and result in a further
inhibition of protein catabolism. Thus a vicious, self-sustaining, cycle
of ever-increasing cellular dysfunction may result in cells exposed to
these agents and material, with this contributing to the cell and tissue
alterations observed in diabetes-associated atherosclerosis.
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